NTRA has drawn a wave of analyst upgrades over the past two weeks. Now the options market is pushing back.
The put/call ratio hit 0.72 on July 8. That's 2.3 standard deviations above its 20-day mean of 0.66. It's the most elevated options hedging seen on the stock in weeks — and it sits against a backdrop of unusually bullish sell-side conviction.
Five firms raised price targets on Natera between June 23 and July 6. Evercore ISI lifted its target to $300. Bernstein reinstated coverage at $310 — the highest target in the group. Guggenheim moved to $290. BTIG raised twice in quick succession, first to $270 then $275. The stock closed July 8 at $274.39.
That means the stock is already trading above three of the five recently revised targets. Bernstein and Evercore remain above the current price. Goldman Sachs sits as the lone dissenter, initiating at Neutral with a $245 target — roughly 11% below where the stock trades today.
The bull case centers on Natera's MRD testing franchise and last week's Japan regulatory approval, which opens an underpenetrated international market. The bear case flags intensifying competition in the MRD landscape and uncertainty around sustaining reimbursement growth.
The PCR spike to 0.72 is notable precisely because it happened as the stock pulled back 2.4% on July 8. It's not at an extreme by historical standards — the 52-week high is 1.24 — but the speed of the move relative to the 20-day mean is what stands out.
Put buying at this pace, relative to recent norms, suggests some participants are buying downside protection. That's not unusual after a 27% one-month rally. But the divergence between analyst optimism and options positioning is worth tracking.
Short interest sits at 3.1% of free float — low enough that the lending market tells no real story. Availability is at 5,725% of short interest, meaning shares to borrow are abundant. Cost to borrow is 0.56% — firmly in "easy" territory. There is no squeeze pressure from the lending side.
Next earnings: August 6. The stock has moved -10% and -2% on its two most recent prints. With the PCR running elevated and the stock near or above most analyst targets, the options market appears to be pricing in some caution ahead of that date.
See the live data behind this article on ORTEX.
Open NTRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
NTRA reports today against a backdrop where its own chief executive has been a notable seller — and that insider activity is the most striking signal heading into the release. CEO Steven Chapman sold roughly $4.8…
Natera enters the stretch toward its June 11 earnings with one of its most distinctly bullish options setups of the past year — a sharp contrast to a stock that has still not recovered all of last month's post-earnings…
